ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 21 of 50
УЖМБС 2021, 6(1): 138–144
Clinical Medicine

Dynamics of Clinical Symptoms and Functional State of the Biliary System in Patients with Chronic Acalculous Cholecystitis on the background of Type 2 Diabetes Mellitus under the Influence of Complex Therapy

Tymoshenko Galyna

The urgent problem of modern medical science and practice is the rapid increase of comorbid pathology spreading among the population of the whole world. Among the nosological forms, which are quite often combined with each other, there are cardiovascular system, digestive tract and endocrine diseases, namely type 2 diabetes mellitus. Diseases of the biliary tract, in the form of chronic acalculous cholecystitis, occur in patients with type 2 diabetes more often than in its absence. There is no doubt that the combination of diseases of the gallbladder and type 2 diabetes significantly affects the course and prognosis of both diseases, and the development of complications is one of the main causes of disability and mortality in patients. In this regard, the priority areas of health protection are the search for preventive measures to eliminate the development of diseases, their complications and the amendment of therapeutic patterns. The purpose of the study was to evaluate the efficacy of complex therapy with the addition of ursodeoxycholic acid and alpha-lipoic acid in patients with concomitant chronic acalculous cholecystitis and type 2 diabetes on the basis of studying the dynamics of clinical symptoms and the content of bile acids in blood serum, as well as parameters of cholecystosonography (in overview and dynamic versions). Material and methods. In the course of the study, 62 patients with the combined course of chronic hepatitis and diabetes mellitus were examined. The age of the patients ranged from 44 to 75 years old. The duration of type 2 diabetes was from 1 to 19 years. The group was representative in terms of age and number of male and female probands. Upon admission to the hospital, all patients underwent a thorough examination using generally accepted clinical, laboratory and instrumental studies. Results and discussion. The complex treatment included hypoglycemic drugs, medical nutrition, prescription of antispasmodic and antibacterial therapy, ursodeoxycholic acid drugs at a dose of 15 mg / kg / day for 4 weeks, as well as preparations of alpha-lipoic acid 600 I / V drip for 10 days, followed by oral administration in within 12 weeks. In order to assess the effectiveness of therapy, clinical symptoms, serum levels of fatty acids, indicators of survey and dynamic cholecystosonography were evaluated after 3 months in the dynamics of treatment. Conclusion. The study showed that the addition of ursodeoxycholic acid and alpha-lipoic acid to the complex therapy was accompanied by positive effects due to an improvement in the contractility of the gallbladder, a decrease in the serum fatty acid content, improved the motor and cholesecretory functions of the gallbladder and the clinical condition of patients by eliminating abdominal pain and reducing the percentage of patients with chronic acalculous cholecystitis and type 2 diabetes with manifestations of dyspeptic, neuro-vegetative and asthenic syndromes

Keywords: type 2 diabetes mellitus, bile acids, chronic acalculous cholecystitis, cholecystosonography, ursodeoxycholic acid, alpha-lipoic acid

Full text: PDF (Ukr) 295K

  1. Chhabra A, Grover S, Vill A, Singh AP. Gallbladder disease in type-2 Diabetes mellitus patients. IJMDS. 2013; 2(1): 7-15.
  2. Dedov II, Shestakova MV, Aleksandrov AA, Galstyan GR, Grigoryan OR, Esayan RM, et al. Klinicheskie rekomendatsii «Algoritmy spetsializirovannoy meditsinskoy pomoshchi bolnym sakharnym diabetom» (6-y vypusk) [Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV (6th edition)]. Diabetes mellitus. 2013; 16(1S): 1-120 [Russian]
  3. Wang W, Li N. The association of gallstone disease and diabetes mellitus. A meta-analysis. Saudi Med J. 2014; 35(9): 1005-1012.
  4. Loranskaya ID, Kukushkin ML, Panina NA. Biliarnye disfunktsii i ikh profilaktika [Biliary dysfunctions and their prevention]. Eksper i klin gastroenterol. 2011; 5: 48-52. [Russian]
  5. Radchenko VG, Shabrov AV, Zinoveva EN, Sitkin SI. Zabolevaniya pecheni i zhelchevyvodyashchikh puteĭ: rukovodstvo dlya vracheĭ [Diseases of the liver and biliary tract: a guide for doctors]. SPb: Spetslit; 2011. 526 s. [Russian]
  6. Bajwa N, Bajwa R, Ghumman A, Agrawal RM. The gallstone story: Pathogenesis and epidemiology. Pract Gastroenterol. 2010; 34(9): 11-23.
  7. Timoshenko GYu. Vikovi osoblivosti dinamiki vmistu faktoru rostu fibroblastiv 19 v sirovattsi krovi u khvorikh na tsukroviy diabet 2 tipu ta biliarnu patologiyu [Age-specific features of the dynamics of fibroblast growth factor 19 content in patients with type 2 diabetes and biliary pathology. Visnik problem biologiyi i meditsini. 2020; 1(155): 204-207. [Ukrainian]
  8. Troisi G, Crisciotti F, Gianturco V, D'Ottavio E, Lo Iacono C, Formosa V, et al. The treatment with urso- deoxycholic acid in elderly patients affected by NAFLD and metabolic syndrome: a case-control study. Clin Ter. 2013; 164(3): 203-207.
  9. Makhov VM, Ugryumova LN, Balakhonov AA, Mamiyeva ZA. Ursodezoksikholevaya kislota: vzglyad terapevta [Ursodeoxycholic acid: a therapist's view]. Med sovet. 2017; 5: 112-116. [Russian]
  10. Banerjee B, Shaheen NJ, Martinez JA, Hsu CH, Trowers E, Gibson BA, et al. Clinical Study of Ursodeoxycholic Acid in Barrett's Esophagus Patients. Cancer Prev Res (Phila). 2016; 9(7): 528-533. PMid:26908564 PMCid:PMC4930711
  11. Fujita K, Iguchi Y, Une M, Watanabe S. Ursodeoxycholic Acid Suppresses Lipogenesis in Mouse Liver: Possible Role of the Decrease in β-Muricholic Acid, a Farnesoid X Receptor Antagonist. Lipids. 2017; 52(4): 335-344. PMid:28315136
  12. Zhuravlova LV, Krivonosova OM. Primenenie ursodezoksikholevoy kisloty v kompleksnoy terapii metabolicheskogo sindroma [The use of ursodeoxycholic acid in the complex therapy of metabolic syndrome]. Suchasna gastroenterologiya. 2014; 4(78): 90-96. [Russian]
  13. Anokhina GA, Kharchenko VV, Opanasyuk ND, Lopukh IYa, Yakubovskaya IO. Nekotorye aspekty primeneniya preparatov ursodezoksikholevoy kisloty v sochetanii s ekstraktami rasteniy v lechenii zabolevaniy gepatobiliarnoy sistemy [Some aspects of the use of ursodeoxycholic acid preparations in combination with plant extracts in the treatment of diseases of the hepatobiliary system]. Suchasna gastroenterologiya. 2014; 1(75): 49-54. [Russian]
  14. Mokhort TV. Alfa-lipoevaya kislota: polifaktornoe vliyanie i obosnovanie vozmozhnosteĭ ispolzovaniya pri sakharnom diabete [Alpha lipoic acid: a polyfactorial effect and justification for its use in diabetes mellitus]. Problemi endokrinnoï patologiï. 2017; 3: 55-63. [Russian]
  15. Pop-Busui R, Ang L, Holmes C, Gallagher K, Feldman EL. Inflammation as a therapeutic target for diabetic neuropathies. Curr Diab Rep. 2016; 16(3): 29. PMid:26897744 PMCid:PMC5127166
  16. Vallianou N, Evangelopoulos A, Koutalas P. Alpha-lipoic Acid and diabetic neuropathy. Rev Diabet Stud. 2009 Winter; 6(4): 230-6. PMid:20043035 PMCid:PMC2836194
  17. Festi D, Montagnani M, Azzaroli F, Lodato F, Mazzella G, Roda A, et al. Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases. Curr Clin Pharmacol. 2007; 2(2): 155-177. PMid:18690863
  18. Zhuravlova LV, Krivonosova OM. Aktualni pidkhody do likuvannya khvorykh na tsukrovyi diabet: navchalnyi posibnyk [Relevant go to add ailments to diabetics: a newcomer]. K: Medkniga; 2019. 123 s. [Ukrainian]